Senzime AB (STU:6YC) Debt-to-Asset : 0.06 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Senzime AB Debt-to-Asset?

Senzime AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €0.32 Mil. Senzime AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was €1.63 Mil. Senzime AB's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was €34.63 Mil. Senzime AB's debt to asset for the quarter that ended in Mar. 2025 was 0.06.

Senzime AB Debt-to-Asset Historical Data

The historical data trend for Senzime AB's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Senzime AB Debt-to-Asset Chart

Senzime AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.04

0.03

0.05

Senzime AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															0.03	0.06	0.06	0.05	0.06

Competitive Comparison of Senzime AB's Debt-to-Asset

For the Medical Devices subindustry, Senzime AB's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Senzime AB's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Senzime AB's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Senzime AB's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Senzime AB Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Senzime AB's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.315	+	1.655)	/	37.067
	=	0.05

Senzime AB's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.323	+	1.631)	/	34.626
	=	0.06

Senzime AB (STU:6YC) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Senzime AB Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Senzime AB's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Senzime AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Senzime AB (STU:6YC) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

SNZZF:USA SEZI:Sweden

Address

Verkstadsgatan 8, Uppsala, SWE, 753 23

Website

https://www.senzime.com

Senzime AB is a medical device company providing patient monitoring systems. Its portfolio comprises systems for patient monitoring of neuromuscular function and breathing, typically during and after surgery, and for the intensive care sector. TetraGraph is a system based on EMG technology for neuromuscular monitoring during surgical procedures. ExSpiron 2Xi is a non-invasive monitoring system of respiratory volume and minute ventilation used for in and out patient care. The company operates in Sweden, Germany and the USA. It derives revenue through sales of monitors and associated disposable sensors to hospitals and clinics.

Senzime AB Headlines

No Headlines